Extracorporeal photopheresis as secondline treatment for acute graftversushost

  • Slides: 7
Download presentation
Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from

Extracorporeal photopheresis as second-line treatment for acute graft-versus-host disease: impact on six-month freedom from treatment failure by Emma Das-Gupta, Hildegard Greinix, Ryan Jacobs, Li Zhou, Bipin N. Savani, Brian G. Engelhardt, Adetola Kassim, Nina Worel, Robert Knobler, Nigel Russell, and Madan Jagasia haematol Volume 99(11): 1746 -1752 November 3, 2014 © 2014 by Ferrata Storti Foundation

Pre-transplant, acute GVHD characteristics, and response to ECP stratified by corticosteroidrefractory and -dependent status.

Pre-transplant, acute GVHD characteristics, and response to ECP stratified by corticosteroidrefractory and -dependent status. Emma Das-Gupta et al. Haematologica 2014; 99: 1746 -1752 © 2014 by Ferrata Storti Foundation

Two-year cumulative incidence of developing chronic graft-versus-host disease for all patients. Emma Das-Gupta et

Two-year cumulative incidence of developing chronic graft-versus-host disease for all patients. Emma Das-Gupta et al. Haematologica 2014; 99: 1746 -1752 © 2014 by Ferrata Storti Foundation

Univariate analyses: overall survival, non-response mortality and 6 -month freedom from treatment failure. Emma

Univariate analyses: overall survival, non-response mortality and 6 -month freedom from treatment failure. Emma Das-Gupta et al. Haematologica 2014; 99: 1746 -1752 © 2014 by Ferrata Storti Foundation

Two-year cumulative incidence of non-relapse mortality (NRM) for all patients. Emma Das-Gupta et al.

Two-year cumulative incidence of non-relapse mortality (NRM) for all patients. Emma Das-Gupta et al. Haematologica 2014; 99: 1746 -1752 © 2014 by Ferrata Storti Foundation

(A) Six-month freedom from treatment failure survival for all patients. Emma Das-Gupta et al.

(A) Six-month freedom from treatment failure survival for all patients. Emma Das-Gupta et al. Haematologica 2014; 99: 1746 -1752 © 2014 by Ferrata Storti Foundation

Causes of death: all patients, patients achieving 6 -month freedom from treatment failure, patients

Causes of death: all patients, patients achieving 6 -month freedom from treatment failure, patients not achieving 6 -month freedom from treatment failure. Emma Das-Gupta et al. Haematologica 2014; 99: 1746 -1752 © 2014 by Ferrata Storti Foundation

Extracorporeal photopheresis as secondline treatment for acute graftversushostExtracorporeal photopheresis as secondline treatment for acute graftversushost
Extracorporeal Membrane Oxygenation in Transport Part 1 ExtracorporealExtracorporeal Membrane Oxygenation in Transport Part 1 Extracorporeal
Steroid treatment of acute graftversushost disease grade ISteroid treatment of acute graftversushost disease grade I
International Perspectives in Individualizing Therapy Beyond Secondline TreatmentInternational Perspectives in Individualizing Therapy Beyond Secondline Treatment
Dolutegravir versus LopinavirRitonavir in SecondLine Treatment DAWNING DolutegravirDolutegravir versus LopinavirRitonavir in SecondLine Treatment DAWNING Dolutegravir
Afatinib versus erlotinib for secondline treatment of ChineseAfatinib versus erlotinib for secondline treatment of Chinese